Chandler, Heather L.
Tan, Tao
Yang, Chunlin
Gemensky-Metzler, Anne J. http://orcid.org/0000-0002-2644-3534
Wehrman, Rita F.
Jiang, Qiwei
Peterson, Cornelia M. W.
Geng, Bingchuan
Zhou, Xinyu
Wang, Qiang
Kaili, Denis
Adesanya, T. M. Ayodele
Yi, Frank
Zhu, Hua http://orcid.org/0000-0001-7136-7326
Ma, Jianjie
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK112403, DK106394)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM123887)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR067766, AG056919, AR061385, AR070752)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL124122)
Article History
Received: 7 June 2018
Accepted: 15 January 2019
First Online: 20 February 2019
Competing interests
: J.M. is a founder of TRIM-edicine, Inc. and T.T. has an equity interest in TRIM-edicine, Inc., a biotechnology company developing rhMG53 as a therapeutic protein. The remaining authors declare no competing interests.